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The adipokine lipocalin-2 in the 
context of the osteoarthritic 
osteochondral junction
Amanda Villalvilla1, Adela García-Martín2, Raquel Largo1, Oreste Gualillo3, Gabriel Herrero-
Beaumont1 & Rodolfo Gómez4
Obesity and osteoarthritis (OA) form a vicious circle in which obesity contributes to cartilage 
destruction in OA, and OA-associated sedentary behaviour promotes weight gain. Lipocalin-2 (LCN2), 
a novel adipokine with catabolic activities in OA joints, contributes to the obesity and OA pathologies 
and is associated with other OA risk factors. LCN2 is highly induced in osteoblasts in the absence of 
mechanical loading, but its role in osteoblast metabolism is unclear. Therefore, because osteochondral 
junctions play a major role in OA development, we investigated the expression and role of LCN2 in 
osteoblasts and chondrocytes in the OA osteochondral junction environment. Our results showed 
that LCN2 expression in human osteoblasts and chondrocytes decreased throughout osteoblast 
differentiation and was induced by catabolic and inflammatory factors; however, TGF-β1 and IGF-1 
reversed this induction. LCN2 reduced osteoblast viability in the presence of iron and enhanced the 
activity of MMP-9 released by osteoblasts. Moreover, pre-stimulated human osteoblasts induced LCN2 
expression in human chondrocytes, but the inverse was not observed. Thus, LCN2 is an important 
catabolic adipokine in osteoblast and chondrocyte metabolism that is regulated by differentiation, 
inflammation and catabolic and anabolic stimuli, and LCN2 expression in chondrocytes is regulated in a 
paracrine manner after osteoblast stimulation.
Obesity and osteoarthritis (OA) show a reciprocal relationship. Among the comorbidities associated with obesity, 
OA is of special interest because this disease is a contributing factor to weight gain1,2. OA is the most common 
rheumatic disease and is characterized by progressive degradation of the articular cartilage3 and by severe altera-
tions such as loss of joint architecture, pain, and disability, which significantly contribute to sedentary behaviour1. 
This sedentary lifestyle is a well-known factor associated with weight gain and obesity2, which enhances carti-
lage degradation due to mechanical joint overload4 and altered metabolism4, including dysregulated adipokine 
production5.
Although OA is considered to be a disease of the whole joint, there is a growing interest in the OA altera-
tions that affect the functional unit formed by the articular cartilage and the underlying subchondral bone6. 
Indeed, both tissues work together to dissipate the mechanical stress that results from joint movement. 
However, subchondral bone also contributes to the maintenance of cartilage homeostasis and integrity6,7. 
Accordingly, biochemical and structural alterations in the subchondral bone may alter cartilage function 
and load-bearing distribution, which in turn may promote cartilage degradation6,8,9. Likewise, abnormal 
mechanical loading and biochemical alterations in the cartilage are associated with aberrant metabolism in 
the subchondral bone, including the production of pro-inflammatory factors and the overexpression of certain 
anabolic factors8,10.
OA joint inflammation is mediated, in part, by innate immune responses elicited by molecules such as 
interleukin-1 beta (IL-1β ) and Toll-like receptor 4 (TLR4) agonists (host-derived molecules generated upon 
tissue damage)11. The activities of these molecules affect both the articular cartilage and the subchondral bone11,12 
and are associated with cartilage degradation11,13, changes in osteoblast phenotype11,14, and alterations in the 
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bone-cartilage crosstalk11,14. In light of these actions, others have suggested that inflammatory and catabolic fac-
tors present in the OA cartilage can reach the OA subchondral bone, and the ones present in the OA subchondral 
can also reach the OA cartilage12,14,15. Although the crosstalk between these tissues has been investigated, a limited 
number of in vitro mechanistic studies have been performed, and thus the precise factors involved in the molec-
ular crosstalk between chondrocytes and osteoblasts are poorly understood.
At the crossroads of several OA risk factors, such as obesity, altered mechanical loading, joint inflammation 
and ageing, is lipocalin-2 (LCN2)5,16, a mechanoresponsive adipokine induced by pro-inflammatory factors in 
joint tissues, whose circulating levels are elevated in obese and aged individuals5,17–19. LCN2 is a 25 kDa glyco-
protein that forms covalent complexes with matrix metalloproteinase 9 (MMP-9)20. LCN2 expression has been 
investigated in joint tissues21–24. In chondrocytes, LCN2 expression is induced upon stimulation with inflam-
matory factors21. Accordingly, increased levels of LCN2 have been found in OA synovial fluid (SF)22,23,25 and 
OA cartilage25. Consistently with this observation, LCN2 promotes cartilage breakdown by blocking MMP-9 
auto-degradation22 and by reducing chondrocyte viability23,26,27. In contrast to its role in cartilage, information 
about the role of LCN2 in bone metabolism is limited. LCN2 expression in osteoblasts is increased by tumour 
necrosis factor (TNF) and IL-1728 and in the absence of mechanical force stimulation24. Additionally, elevated cir-
culating levels of LCN2 have been correlated with an increased risk of osteoporotic fractures in aged individuals18, 
and mice overexpressing LCN2 are smaller than their wild-type littermates and exhibit bone alterations29.
The subchondral bone plays a major role in OA pathophysiology. Therefore, considering the catabolic activ-
ities of LCN2 in other joint tissues, we investigated the role of LCN2 in osteoblast metabolism by mimicking the 
OA osteochondral junction environment. Our results revealed that LCN2 expression was decreased throughout 
osteoblast differentiation but was induced by catabolic and inflammatory factors. Conversely, anabolic factors 
blocked this induced expression. LCN2 affected osteoblast viability and promoted MMP-9 activity. Furthermore, 
stimulated osteoblast conditioned medium induced LCN2 expression in human chondrocytes, whereas LCN2 
induction in these cells was inhibited by anabolic factors.
Materials and Methods
Reagents. Foetal bovine serum (FBS), alpha-MEM medium, Dulbecco’s modified Eagle’s medium (DMEM), 
antibiotics, trypsin, and L-glutamine were purchased from Lonza (Verviers, Belgium). IL-1β and IGF-1 were 
purchased from PeproTech (Rocky Hill, NJ, USA). Dexamethasone (Dx) was obtained from Merck & Co. 
(Kenilworth, NJ, USA). Collagenase IV, lipopolysaccharide (LPS; E. coli 055:B5), L-ascorbic acid, β -glycerophos-
phate, transforming growth factor-beta 1 (TGF-β 1), methyl-thiazolyl-tetrazolium (MTT) dye, and ferric ammo-
nium citrate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant mouse LCN2 and goat 
anti-human LCN2 antibodies were obtained from R&D Systems (Minneapolis, MN, USA). Unless otherwise 
specified, all reagents were purchased from Sigma-Aldrich.
Cell culture. Human tissues were obtained from patients who had undergone total knee replacement surgery. 
The Ethics Committee for Clinical Research at the Fundación Jiménez Díaz (FJD) Institute approved the protocol, 
and written informed consent was obtained from all patients. All processes were carried out according to relevant 
guidelines and regulations. Human chondrocytes were obtained as previously described30. Human osteoblasts 
were obtained by culturing bone pieces in culture dishes with DMEM containing 20% heat-inactivated FBS, 
2 mM glutamine, and 100 U/ml of penicillin/streptomycin, and experiments were performed using cells at the 
third passage.
Mouse osteoblast precursor MC3T3-E1 cells were grown in alpha-MEM with 10% inactivated FBS, 4 mM glu-
tamine, and 100 U/ml of penicillin/streptomycin. To induce differentiation, cells were seeded at 2.5 × 104 cells/cm2, 
and the growth medium was exchanged with differentiation medium containing normal medium supplemented 
with 50 μ g/ml L-ascorbic acid and 10 mM β -glycerophosphate.
Cell treatment. Human primary cells were seeded onto 6-well plates and grown until confluence. MC3T3 
cells (2 × 105 cells per well) were also seeded onto 6-well plates. After culturing under serum-free conditions, 
or under 1% heat-inactivated FBS for human osteoblasts, cells were treated for 48 h with conditioned medium 
(CM) or the following stimuli alone or in combination: 1 μ g/ml LPS, 1 ng/ml IL1β , 10 μ M Dx, 10 ng/ml TGF-β 1 
(selected dose to mimic the overproduction observed in OA subchondral bone and to promote signalling through 
SMADs 2/3 and 1/5/831), and 100 ng/ml IGF1. MC3T3 cells were also differentiated for 15 days and then treated 
with 10 μ M Dx for 48 h as a de-differentiation factor for osteoblasts.
To obtain CM, cells were stimulated with IL-1β for 24 h and washed three times with serum-free medium. 
Fresh serum-free medium was subsequently added, and cells were cultured for 24 h. Then, CM was collected, 
sterile-filtered to remove cell debris and frozen until use.
Cell transfection. MC3T3 cells were transfected with pCMV6-AC-GFP or pCMV6-LCN2-GFP (OriGene 
Technologies Inc., Rockville, MD, USA) using the X-tremeGENE HP DNA Transfection Reagent (Roche Applied 
Science, Mannheim, Germany) according to the manufacturer’s instructions. Briefly, 2 × 105 cells/well were 
seeded onto 6-well plates and grown for 24 h. Then, the culture medium was replaced with serum-free medium, 
and cells were transfected using 3 μ l of reagent and 1 μ g of DNA per well. After 24 h of incubation, the transfec-
tion medium was replaced with growth medium. Then, the cells were cultured for 24 h, and CM was collected, 
sterile-filtered, and frozen. The transfected cells were lysed with Tripure reagent (Roche Diagnostics, Indianapolis, 
IN, USA) for RNA isolation.
Gene expression analysis. After treatment, cells were lysed in Tripure reagent or RP1 buffer pro-
vided with a Nucleospin RNA/Protein Isolation Kit (Macherey-Nagel, Düren, Germany), and RNA was iso-
lated according to the manufacturer’s protocol. cDNA was synthesized using a High-Capacity cDNA Reverse 
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Transcription Kit (Applied Biosystems, Life Technologies, Grand Island, NY, USA). The mRNA expression lev-
els of lipocalin-2 (LCN2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), and bone 
gamma-carboxyglutamate protein (osteocalcin) were determined by real-time PCR using TaqMan gene expres-
sion assays (Applied Biosystems). The data were normalized using hypoxanthine phosphoribosyltransferase 
(HPRT) for human cells and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for murine cells, and data 
were expressed as the fold-change versus the unstimulated control or as a percentage of stimulated cells.
Western blot analysis. Proteins were isolated using a Nucleospin RNA/Protein Isolation Kit. Twenty-five 
micrograms of protein from each sample was loaded and resolved on a 10% SDS-PAGE gel. Proteins were subse-
quently transferred to a polyvinyl difluoride (PVDF) membrane. To avoid interference between antibodies, the 
membranes were cut according to the molecular weight of the studied proteins and incubated with the corre-
sponding antibody: goat anti-human LCN2 antibody (the lower part) or anti-human actin (the upper part). The 
antibody binding was visualized by enhanced chemiluminescence with the corresponding peroxidase-conjugated 
secondary antibody and Immobilon Western Detection kit (EMD Millipore, Billerica, MA, USA). To confirm 
equal loading of each sample, the expression of LCN2 was normalized to actin expression. The images were cap-
tured using ImageQuant LAS 4000 (GE Healthcare Life Sciences, Piscataway, NJ, USA) and analysed with ImageJ 
software (ImageJ v1.45s, NIH, Bethesda, MD, USA).
Cell viability assay. Viability was tested using the MTT reagent. To perform the assay, 3 × 103 cells/well 
were plated onto 96-well plates and treated with CM from cells that were non-transfected or transfected with 
either LCN2 or vector plasmid MC3T3, in the presence or absence of 0.5 μ g/ml or 1 μ g/ml of ferric ammonium 
citrate (FCA) for 68 h. Then, 0.5 mg/ml of MTT reagent was added, and after 4 h of incubation, formazan salt was 
dissolved in dimethyl sulfoxide (DMSO). Absorbance was measured at 570 nm with an Infinite 200 microplate 
reader (Tecan Group Ltd., Männedorf, Switzerland).
Zymography. LCN2 stabilization of MMP-9 activity was determined by gelatine zymography. CM from 
MC3T3 cells was collected to detect MMP-9 activity. CM was mixed with increasing concentrations of recombi-
nant mouse LCN2 and incubated for 1 h at 37 °C. Then, equal volumes were loaded onto a 10% polyacrylamide gel 
containing 0.1% gelatine, and proteins were separated by SDS/PAGE under non-reducing conditions at 4 °C. After 
this electrophoresis, the gels were washed with 2.5% Triton X-100 and incubated with proteolysis buffer (50 mM 
Tris–HCl pH 7.6, 0.2 mM NaCl, and 5 mM CaCl2, 0.2% NP-40 and 0.01% Tween 20) for 20 h at 37 °C. Next, the 
gels were incubated with staining buffer (0.05% Coomassie blue, 50% methanol, and 10% acetic acid), followed by 
destaining buffer (4% methanol and 8% acetic acid). The gels were scanned using a Gel Doc EZ scanner (Bio-Rad, 
Hercules, CA, USA) and analysed and quantified using ImageJ (ImageJ v1.45s).
Statistical analysis. Data are expressed as the mean ± standard error of the mean (SEM) for at least three 
independent experiments. Significant differences were assessed using a one-way analysis of variance (ANOVA) 
or the Kruskal-Wallis test, followed by a Bonferroni or Dunn post-test, respectively, or Student’s t test or 
Mann-Whitney test when appropriate. All analyses were performed using Prism software (GraphPad Software 
Inc., La Jolla, CA, USA), and p < 0.05 was considered significant.
Results
LCN2 expression in osteoblast differentiation. LCN2 is involved in the differentiation of several cell 
types21,32. Because osteoblasts from OA subchondral bone exhibit altered differentiation12, we investigated the 
expression of LCN2 during osteoblast differentiation. LCN2 expression was inhibited throughout the differen-
tiation of the mouse osteoblastic MC3T3 cells, and was negatively related to matrix mineralization and to the 
expression of osteoblastic markers (Fig. 1). However, neither exogenous LCN2 addition nor transient LCN2 
overexpression in these cells affected the expression of osteoblastic markers (data not shown). Hence, we tested 
whether LCN2 expression was associated with osteoblast de-differentiation by studying the effect of a known 
inhibitor of osteoblast differentiation33, specifically a high dose of Dx (10 μ M), on LCN2 expression. MC3T3 cells 
differentiated for 15 days showed induced LCN2 expression (Fig. 1F) and inhibited ALP expression (Fig. 1G) after 
Dx treatment.
LCN2 expression is enhanced by inflammatory/catabolic factors. LCN2 is a catabolic adipokine 
induced by inflammatory stimuli in several joint tissues27. Therefore, given that OA subchondral bone is exposed 
to multiple inflammatory and catabolic factors, we stimulated MC3T3 cells for 48 h with joint inflammatory 
factors, IL-1β (1 ng/ml) or the TLR4 agonist LPS (1 μ g/ml), to test their effect on LCN2 expression. Both fac-
tors strongly enhanced the expression of LCN2 in these cells (Fig. 2A). Consistently with these results, IL-1β 
and LPS also induced the expression of LCN2 mRNA and protein in human primary osteoblasts (Fig. 2B,C). 
Given the anti-inflammatory properties of Dx and its catabolic activities at high concentration, we studied 
the combined effect of these inflammatory factors and Dx (10 μ M) on LCN2 expression. Independently of the 
anti-inflammatory properties of Dx21, IL-1β and LPS synergized with Dx in the induction of LCN2 expression in 
MC3T3 cells (Supplementary Fig. S2) and in human primary osteoblasts (Supplementary Fig. S3).
Effects of LCN2 on osteoblast viability and MMP-9 activity. LCN2 has been associated with cell 
viability regulation23,26,27. Therefore, to evaluate the potential consequences of the increased expression of LCN2 
mediated by inflammatory stimuli, we investigated the effects of LCN2 on osteoblast viability. To mimic the 
induction of LCN2 observed in the stimulated osteoblasts and to isolate its effects on their viability, we generated 
LCN2-enriched medium by overexpressing LCN2 in MC3T3 cells (Supplementary Fig. S4). This overexpression 
did not affect the cell viability (data not shown). Likewise, the culture of MC3T3 osteoblasts in the obtained 
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LCN2-enriched medium also did not affect cell viability (Fig. 3A). However, given the role of LCN2 on iron 
metabolism34 and the role that iron plays in osteoblast viability35,36, we found that LCN2-enriched medium signif-
icantly enhanced the inhibition of the osteoblast viability caused by the iron donor FCA (Fig. 3B).
LCN2 protects MMP-9 against auto-degradation, thus enhancing its catabolic activities22. Because MMP-9 
is involved in bone remodelling, including in the OA subchondral bone37,38, we used gelatine zymography to 
determine whether exogenous LCN2 would enhance the MMP-9 activity present in the CM from MC3T3 
cells. Incubation of this CM with a suitable dose of LCN2 (30 ng/μ l), selected after dose-response experiments 
(Supplementary Fig. S5), induced an increase in MMP-9 activity at the band sizes corresponding to the mono-
meric and dimeric forms of the complex LCN2/MMP-9 (Fig. 3C,D).
LCN2 expression is inhibited by anabolic factors in osteoblasts. Mechanical loading enhances osteo-
blast survival and bone formation24,39. Because LCN2 expression is highly induced in the absence of this stimulus24, 
we investigated whether IGF-1 and TGF-β 1, two bone anabolic factors often related to OA pathophysiology and 
Figure 1. Evaluation of MC3T3 cell differentiation. MC3T3 cells were differentiated for 2, 15 or 29 days 
in the presence of 50 μ g/ml L-ascorbic acid and 10 mM β -glycerophosphate. Then, matrix mineralization 
was evaluated using alizarin red staining (A), and LCN2 (B), ALP (C), Runx2 (D) and osteocalcin (E) gene 
expression was evaluated by real-time PCR. MC3T3 cells were differentiated for 15 days as described above 
and then were treated for 48 h with the de-differentiating factor 10 μ M dexamethasone (Dx) to measure LCN2 
(F) and ALP (G) gene expression. The results are presented as the mean ± SEM of at least three independent 
experiments. * p < 0.05; * * p < 0.01; * * * p < 0.001.
www.nature.com/scientificreports/
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bone mechanical loading8,40–42, would modulate LCN2 expression in human osteoblasts. Unlike TGF-β 1, IGF-1 
did not inhibit LCN2 basal expression (Fig. 4A). However, TGF-β 1 and IGF-1 stimulation of osteoblasts inhibited 
IL-1β - and LPS-mediated LCN2 expression (Fig. 4B–E).
Effect of osteoblast-chondrocyte bidirectional crosstalk on LCN2 expression. The subchondral 
bone and the articular cartilage are tightly related. Therefore, we studied whether the crosstalk between osteo-
blasts and chondrocytes would affect the expression of LCN2. Accordingly, we treated human chondrocytes with 
CM from osteoblasts pre-stimulated with IL-1β or treated human osteoblasts with the CM from chondrocytes 
pre-stimulated with IL-1β . The CM from the pre-stimulated osteoblasts induced the expression of LCN2 in chon-
drocytes (Fig. 5A). In contrast, the CM from the pre-stimulated chondrocytes did not induce any significant 
changes in the expression of LCN2 in osteoblasts (Fig. 5B).
LCN2 expression is modulated by inflammatory and anabolic factors in chondrocytes. OA 
cartilage is usually exposed to a pro-inflammatory environment that may enhance LCN2 expression and, there-
fore, cartilage degradation22,27. Consistently with this assumption, IL-1β and LPS stimulation induced the expres-
sion of LCN2 in human primary chondrocytes (Fig. 5C). Moreover, given the key role of several growth factors 
in OA pathophysiology, we investigated whether LCN2 expression in these cells was also modulated by IGF-1 
and TGF-β 1. Interestingly, none of these growth factors inhibited the basal expression of LCN2 in chondrocytes 
Figure 2. Effect of pro-inflammatory stimuli on LCN2 expression in murine and human osteoblasts. Non-
differentiated MC3T3 cells were stimulated with 1 μ g/ml LPS or 1 ng/ml IL-1β for 48 h to evaluate LCN2 gene 
expression (A). Human osteoblasts were grown until confluence and, after overnight culture in 1% FBS, cells 
were stimulated with 1 μ g/ml LPS or 1 ng/ml IL-1β for 48 h. LCN2 mRNA expression was measured by real-time 
PCR (B). LCN2 protein expression was determined by western blot analysis and quantified by densitometry. 
Cropped images of the blots are shown. Full-length blots are presented in Supplementary Fig. 1. Gels were 
run under the same experimental conditions. (C). The results are presented as the mean ± SEM of at least four 
independent experiments and expressed as the fold-change over the control (* p < 0.05, * * * p < 0.001).
www.nature.com/scientificreports/
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(Fig. 5C). Nonetheless, TGF-β 1 inhibited the expression of LCN2 induced by IL-1β or LPS (Fig. 5D,E), whereas 
IGF-1 inhibited only IL-1β -mediated LCN2 expression (Fig. 5F,G).
Discussion
In this work, we present evidence indicating that the expression of the obesity-related adipokine LCN2 is inhib-
ited throughout osteoblast differentiation and is induced in osteoblasts and chondrocytes exposed to OA-related 
inflammatory stimuli. However, this induction was strongly blocked by IGF-1 and TGF-β 1. We further show that 
LCN2 decreases the viability of iron-overloaded osteoblasts and enhances the activity of the osteoblast-released 
MMP-9. Finally, we show that CM from osteoblasts stimulated with an inflammatory factor (IL-1β ) enhances the 
expression of LCN2 in chondrocytes.
Obesity and OA are two closely related pathologies that form a vicious cycle. Obesity promotes cartilage deg-
radation due to excessive mechanical loading and an aberrant metabolic environment4,5, whereas cartilage degra-
dation involves joint failure, pain and disability, which are associated with a sedentary lifestyle1. Indeed, sedentary 
behaviour is linked to weight gain and obesity development. Additionally, obesity has also been associated with 
low bone quality43,44, which in turn has been associated with enhanced cartilage damage in OA animal models45.
Figure 3. Effects of LCN2 gene expression in MC3T3 cells. Twenty-four hour CM from MC3T3 cells 
transfected with empty vector (CM vector) or LCN2-containing plasmid (CM LCN2) was used to stimulate 
MC3T3 cells for 48 h. The effect of LCN2-enriched medium on cell vitality was determined by the MTT 
assay in the absence (A) or presence (B) of an iron donor (ferric citrate ammonium, FCA) at 0.5 or 1 μ g/ml. 
Additionally, 30 ng/μ l of recombinant mouse LCN2 was incubated for 1 h at 37 °C with MC3T3 cell CM to 
detect the effect of LCN2 on MMP-9 activity by gelatine zymography. A cropped image of the gel is shown. The 
full-length gel is presented in Supplementary Fig. 6. (C). Gelatinolytic activity was measured by densitometry 
for both the MMP-9/LCN2 monomer and dimer (D). The results are presented as the mean ± SEM of at least 
three independent experiments and expressed as a percentage of the non-stimulated control (B,D) (* p < 0.05,  
* * p < 0.01, * * * p < 0.001).
www.nature.com/scientificreports/
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Figure 4. Effect of anabolic factors on LCN2 expression in primary human osteoblasts. Human osteoblasts 
were grown until confluence. After overnight culture in 1% FBS, cells were stimulated with 10 ng/ml TGF-β 1 
or 100 ng/ml IGF-1 alone (A) or in combination with 1 μ g/ml LPS (B,D) or 1 ng/ml IL-1β (C,D) for 48 h. Then, 
LCN2 mRNA expression was measured by real-time PCR. The results are presented as the mean ± SEM of at 
least four independent experiments and expressed as a fold-change over the control (A) or as the percentage 
over the stimulated control (B–E) (* p < 0.05, * * * p < 0.001).
www.nature.com/scientificreports/
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Accordingly, to investigate the potential relationship between these pathologies, we focused on the study of the 
osteochondral junction because this interface plays a major role in OA development8,10,46. Abnormal mechanical 
Figure 5. Modulation of LCN2 in osteoblast-chondrocyte crosstalk and in primary human chondrocytes. 
Primary human osteoblasts and chondrocytes were grown until confluence and stimulated with 1 ng/ml IL-1β 
for 24 h. After washing, CM was collected and used to stimulate human chondrocytes (A) or osteoblasts (B). 
Primary human chondrocytes were grown until confluence and then stimulated with 10 ng/ml TGF-β 1,  
100 ng/ml IGF-1, 1 μ g/ml LPS or 1 ng/ml IL-1β alone (C) or with combined anabolic and pro-inflammatory 
factors (D–G) for 48 h. LCN2 mRNA expression was measured by real-time PCR. The results are presented 
as the mean ± SEM of at least four independent experiments and expressed as the fold-change over the non-
stimulated CM (A,B), non-stimulated control (C) or as the percentage over the stimulated control  
(D–G). (* p < 0.05, * * * p < 0.001, ns: non-significant).
www.nature.com/scientificreports/
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loading on OA joints has been related to aberrant metabolism and turnover of the subchondral bone8,10. As a 
result, OA subchondral bone exhibits a complex structure with sclerotic and osteoporotic regions45,46. This hetero-
geneous structure affects the mechanical stress distribution on the cartilage, thereby promoting its degradation46. 
Accordingly, because cartilage and subchondral bone are thought to act as a functional unit6, and considering that 
the obesity-related adipokine LCN2, an articular catabolic adipokine, is highly induced in osteoblasts under an 
unloading stimulus17,24, we decided to investigate the role of LCN2 in osteoblast and chondrocyte metabolism by 
mimicking the OA osteochondral junction environment.
In this work we found that LCN2 expression was down-regulated throughout osteoblast differentiation. In 
contrast, LCN2 expression has been reported to increase during primary murine osteoblast differentiation29. 
However, in this work, Dx was added to the differentiation medium, which may explain the induction of LCN2. 
In fact, osteoblast de-differentiation promoted by a high Dx concentration33 induced LCN2 expression. Although 
this result suggests that LCN2 inhibition may be involved in osteoblast differentiation, none of our approaches 
involving treating or overexpressing LCN2 in MC3T3 cells induced any change in the expression of osteoblast dif-
ferentiation markers (data not shown). Nonetheless, Rucci et al. have shown that LCN2 overexpression in human 
osteoblasts inhibits the expression of several differentiation markers17.
OA subchondral bone osteoblasts are exposed to multiple inflammatory factors, which may originate from 
other inflamed tissues or from osteoblasts exposed to an excessive mechanical loading or inflammatory stimuli10,47. 
According to this scenario, LCN2 expression is induced in murine and human osteoblasts upon stimulation 
Figure 6. Speculative model of LCN2 regulation in the OA osteochondral junction. In the presence of 
alterations in articular biomechanics, joint tissues are subjected to different amounts of loading. Where the 
mechanical load is increased, LCN2 expression is decreased in bone, along with the up-regulation of growth 
factors, such as TGF-β 1 and IGF-1, which might contribute to reduced LCN2 expression in osteoblasts. In this 
way, the bone exhibits higher bone formation and subchondral sclerosis. In areas of lower mechanical load, 
LCN2 expression is increased. In osteoblasts, this expression is enhanced by pro-inflammatory factors, which 
may originate from loaded bone and the inflamed environment. High LCN2 expression may have deleterious 
effects on bone, promoting MMP-9 activity and contributing to reduced osteoblast viability. Pro-inflammatory 
factors and other mediators derived from different joint tissues, including subchondral bone, may also induce 
LCN2 expression in the articular cartilage. Although TGF-β 1 and IGF-1 also inhibit the induced expression of 
LCN2 in chondrocytes, impairment of their signalling pathways by oxidative stress, ageing, etc. may block this 
inhibition, thus leading to greater LCN2 expression and cartilage degradation during OA. Black lines indicate 
data described in this work, and grey dotted lines indicate data previously described8,17,24,51.
www.nature.com/scientificreports/
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with IL-1ß and a TLR4 agonist (LPS), thus suggesting that inflammation may induce LCN2 expression in OA 
subchondral bone osteoblasts. Interestingly, as found in chondrocytes21, despite the anti-inflammatory proper-
ties of Dx, osteoblast stimulation with Dx enhanced inflammation-mediated LCN2 expression, which has been 
recently associated with the cooperative recruitment of NFκ B, C/EBPβ and the glucocorticoid receptor to the reg-
ulatory regions of LCN2 in an Iκ Bζ -dependent manner48. Together, these results suggest that the use of corticoids 
in OA joints might contribute to the alteration of LCN2 metabolism in the subchondral bone.
Because inflammation strongly induces LCN2 expression in osteoblasts, and obesity and ageing, two major 
OA risk factors, are characterized by elevated LCN2 circulating levels, we investigated the effects of LCN2 on 
osteoblast metabolism. Although LCN2 has been shown to modulate cell viability in other cell types, including 
chondrocytes23,26,27, LCN2-enriched medium did not affect MC3T3 cell viability. Nonetheless, LCN2 has been 
shown to play a role in iron metabolism34, which has a strong effect on osteoblast viability35,36, and LCN2-enriched 
medium significantly enhanced the reduction of osteoblasts viability caused by iron overload. Supporting this 
role, LCN2 exhibits a similar mechanism in cell viability regulation in cardiomyocytes49.
Altogether, the effect of LCN2 on iron metabolism in osteoblasts and the ability of LNC2 to increase the activ-
ity of the bone resorption protease MMP-937,38 strongly suggest that LCN2 is a new catabolic factor in bone tissue.
TGF-β 1, a growth factor associated with bone growth8, is overexpressed in OA sclerotic subchondral bone, 
and its expression and activity are enhanced by mechanical stimulation8,40,42. Likewise, IGF-1 signalling is 
over-activated in OA sclerotic subchondral bone50, and its activity is blocked in bone exposed to an unloading 
stimulus41. Hence, different regions of the OA subchondral bone are associated with different activities of these 
growth factors. According to the catabolic activities of LCN2 described in this work, the observation that IGF-1 
and TGF-β 1 inhibited the inflammation-mediated LCN2 expression in human osteoblasts suggests that LCN2 
inhibition might contribute to growth factor-mediated bone formation, which in turn may participate in the gen-
eration of OA subchondral bone sclerosis. Consistently with this idea, we also found that TGF-β 1 inhibited LCN2 
basal expression. Nonetheless, the confirmation of involvement of LCN2 in these alterations will require specific 
in vivo experiments showing an altered distribution of this adipokine in OA subchondral bone.
IGF-1 and TGF-β 1 also play key roles in cartilage physiology and pathophysiology8,51. TGF-β 1 participates in 
cartilage homeostasis52 and mediates the response of chondrocytes to mechanical loading8. Additionally, IGF-1 
promotes chondrocyte proliferation and proteoglycan synthesis53,54. Given the catabolic activities of LCN2 on 
cartilage5,22, the observation that TGF-β 1 inhibited the inflammation-mediated LCN2 expression in chondro-
cytes therefore suggests that TGF-β 1 activity in cartilage might prevent the catabolic activities of LCN2. Likewise, 
IGF-1 may also prevent these catabolic activities because this growth factor also inhibited IL-1ß-mediated LCN2 
expression in these cells. Nonetheless, it is notable that the OA environment (chondrocyte differentiation, ageing 
and oxidative stress) may disrupt the inhibitory properties of these growth factors8,51.
Biochemical and mechanical alterations in OA cartilage affect the OA subchondral bone and the ones in 
the OA subchondral bone affect the OA cartilage6. However, only osteoblasts induced the paracrine expression 
of LCN2 in chondrocytes, which suggests that the OA subchondral bone might contribute to increased LCN2 
expression in the OA cartilage, thus linking the subchondral bone inflammatory state to cartilage catabolism.
Finally, we propose a speculative model of LCN2 regulation in the OA osteochondral junction to help integrate 
the current knowledge of LCN2 modulation by mechanical stimuli in the bone, the data obtained in this work, and 
the diverse phenotypes of OA subchondral bone (Fig. 6). We suggest that the expression of LCN2 and its associated 
catabolic activities in the OA osteochondral junction might have a heterogeneous distribution. Hence, the maximum 
expression of this catabolic adipokine would be localized at regions exposed to the lowest mechanical loading and 
elevated inflammatory factors, and in environments with little or no growth factor signalling. We also suggest that 
the elevated circulating levels of LCN2 in obese and aged individuals might contribute to OA joint alterations5,17–19.
In conclusion, the data presented herein reveal a new facet of LCN2, the obesity-associated adipokine, as a cat-
abolic factor in bone that is regulated in osteoblasts by inflammatory, catabolic, and anabolic factors. Additionally, 
we show that LCN2 expression in chondrocytes is regulated by osteoblasts through a paracrine mechanism and 
by the same factors that regulate its expression in osteoblasts. Overall, these results, together with the catabolic 
properties of LCN2 in other joint tissues, suggest that LCN2 is an active catabolic agent in OA joints that serves as 
a link among obesity, ageing and OA joint alterations.
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